Clinical Trial Update: A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for BLEX 404 Oral Liquid in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. The study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• BLEX 404 Oral Liquid

Snippet

Sponsor: BioLite, Inc. | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: NOT_YET_RECRUITING